子宫内膜癌的分子分型及其与无复发生存和总生存结局的关联:GOG-0258辅助分析
GOG-0258Ⅲ期随机试验的辅助分析,用错配修复(MMR)和p53蛋白表达对子宫内膜癌分子分型,比较化疗联合放疗(CRT)与单纯化疗(CT)的生存结局。p53异常型5年无复发生存(RFS)和总生存(OS)最差,dMMR型与p53野生型相比无显著差异。探索性分析中p53野生型患者CRT较CT改善RFS,各亚组OS无差异。
要点
- p53异常型子宫内膜癌5年RFS为29%,HR=3.39(95%CI 2.34-4.91),较p53野生型显著更差。
- p53异常型5年OS为39%,HR=4.64(95%CI 3.16-6.79),较p53野生型显著更差。
- 探索性分析中p53野生型患者CRT较CT改善RFS(77% vs 60%,HR=0.54,95%CI 0.32-0.94)。
核心结论
- 分子分型似乎具有预测和预后价值,p53异常型肿瘤患者生存更差。
- 探索性分析中p53野生型似乎预测CRT较CT改善RFS。
- 按分子亚型分析,OS的治疗疗效无差异。
研究设计与样本
- GOG-0258Ⅲ期随机试验(NCT00942357)的辅助分析,比较CRT与CT。
- 采用免疫组化评估MMR和p53状态,用Kaplan-Meier曲线和校正Cox模型分析生存结局。
主要发现
- 子宫内膜癌分型:dMMR占27%,p53异常占24%,p53野生型占49%。
- p53异常型在年龄较大、Black种族和浆液性组织学患者中更常见(p < 0.001)。
- 中位随访113个月,p53异常型5年RFS为29%(HR=3.39,95%CI 2.34-4.91),5年OS为39%(HR=4.64,95%CI 3.16-6.79),均较p53野生型(参照)差(p < 0.001)。
- dMMR型5年RFS为58%(HR=1.30,95%CI 0.85-1.97),5年OS为77%(HR=1.53,95%CI 0.99-2.36),对照p53野生型为69%和85%。
- 校正年龄、肉眼残留病灶和治疗后,探索性分析中p53野生型CRT较CT改善RFS(77% vs 60%;HR=0.54,95%CI 0.32-0.94)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Determine if molecular classification using mismatch repair (MMR) and p53 protein expression predicts recurrence-free survival (RFS) and overall survival (OS) in endometrial cancer (EC) patients treated with chemotherapy and radiation (CRT) versus chemotherapy (CT). METHODS: GOG-0258, a phase III randomized trial (NCT00942357), compared CRT to CT. Immunohistochemistry assessed MMR and p53 status. Kaplan-Meier curves and adjusted Cox models analyzed survival outcomes by molecular subtype. RESULTS: ECs classified as deficient MMR (dMMR) (27 %), p53 abnormal (p53abn) (24 %), and p53 wild type (p53wt) (49 %). p53abn were more frequent in patients that were older, Black, and had serous histology (p < 0.001). Median follow up was 113 months. Five-year RFS and OS were worse with p53abn (29 % [Hazard Ratio (HR) = 3.39 (95 % Confidence Interval (CI): 2.34-4.91)] and 39 % [HR = 4.64 (95 % CI: 3.16-6.79)] compared to those with p53wt (referent) (p < 0.001). The five-year RFS and OS for dMMR cancers were (58 % [HR = 1.30 (95 % CI: 0.85-1.97)] and 77 % [HR = 1.53 (95 % CI: 0.99-2.36)] compared to those with p53wt (69 % and 85 %). After adjusting for age, gross residual disease, and treatment, p53wt improved RFS with CRT compared to CT in an exploratory analysis (77 % vs 60 %; HR = 0.54 (95 % CI: 0.32-0.94). The 5-year and 10-year OS rates were similar in CRT compared to CT in all subgroups. CONCLUSION: Molecular classification appears to be predictive and prognostic, with worse survival in those with p53abn tumors. In an exploratory analysis, p53wt appears to predict improved RFS, favoring CRT over CT. There was no difference in treatment efficacy based on molecular subtype for OS.
引用
- Clements A, Enserro D, Strickland KC, et al. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynecol Oncol. 2025. PMID: 39854806. doi:10.1016/j.ygyno.2025.01.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。